Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2/3 Multicenter, Randomized, Double-masked, Parallel-group, Placebo-controlled Study to Investigate the Safety, Pharmacokinetics, Tolerability, and Efficacy of ALK-001 in Geographic Atrophy Secondary to Age-related Macular Degeneration

Next Previous
Search
Trial Profile

A Phase 2/3 Multicenter, Randomized, Double-masked, Parallel-group, Placebo-controlled Study to Investigate the Safety, Pharmacokinetics, Tolerability, and Efficacy of ALK-001 in Geographic Atrophy Secondary to Age-related Macular Degeneration

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 14 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gildeuretinol (Primary)
  • Indications Dry age-related macular degeneration
  • Focus Therapeutic Use
  • Acronyms SAGA
  • Sponsors Alkeus Pharmaceuticals

    • Most Recent Events

    • 11 Feb 2025 According to an Alkeus Pharmaceuticals media release, safety and efficacy data from this study will be presented at the 48th Annual Meeting of the Macula Society being held February 12-15 in Charlotte Harbor, Fla.
    • 23 Oct 2024 According to an Alkeus Pharmaceuticals Media Release, Alexander Melamud is the principal investigator of the study.
    • 23 Oct 2024 According to an Alkeus Pharmaceuticals Media Release, Results of this study were presented at the 128th Annual Meeting of the American Academy of Ophthalmology (AAO) held in Chicago October 18-21, 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top